Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimal Combination Therapy After Nevirapine Exposure

Trial Profile

Optimal Combination Therapy After Nevirapine Exposure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OCTANE; OCTANE-1
  • Most Recent Events

    • 07 Mar 2018 Results assessing association between virological failure of ART and HIV variant with dual-class resistance by using data from this study presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5175 trial, were presented at the 9th International AIDS Society Conference on HIV Science
    • 08 Mar 2012 Extension study results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top